Document is current
Any future updates will be listed below
-
Authors
Glaspole, Ian https://orcid.org/0000-0002-5118-2890
Bonella, Francesco
Bargagli, Elena
Glassberg, Marilyn K.
Caro, Fabian
Stansen, Wibke
Quaresma, Manuel
Orsatti, Leticia
Bendstrup, Elisabeth
-
Funding
Funding for this research was provided by:
These trials were funded by Boehringer Ingelheim.
- License Information
-
More Information
Article History
Received: 9 December 2020
Accepted: 24 March 2021
First Online: 26 April 2021
Declarations
:
: These trials were conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and were approved by local authorities. The clinical protocols were approved by an independent ethics committee or institutional review board at each participating centre. All patients provided written informed consent before study entry.
: Not applicable.
: IG reports personal fees from Boehringer Ingelheim, Roche, Menarini, AdAlta, Pulmotect and Accendatech. FB reports personal fees and non-financial support from Boehringer Ingelheim, Roche, Galapagos, Fujirebio, Bristol-Myers Squibb and GlaxoSmithKline. EBa reports no disclosures. MG has served on advisory boards for Bellerophon Therapeutics, Boehringer Ingelheim and Genentech-Roche. FC reports no disclosures. WS, MQ and LO are employees of Boehringer Ingelheim. EBe reports grants and personal fees from Boehringer Ingelheim and Roche.
